Design, Synthesis, and Bioevaluation of Novel NLRP3 Inhibitor with IBD Immunotherapy from the Virtual Screen
Journal of Medicinal Chemistry · 26.09.2024 · 67 (18) · 16612-16634
DOI: 10.1021/acs.jmedchem.4c01445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 13.09.2024. Verfasst von Ziwen Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy & Minhang Hospitol, Fudan University, Shanghai 201301, China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Drug Design. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Institute of Fudan University-Quzhou.
Abstract (Originalsprache)
NLRP3, a crucial member of the NLRP family, plays a pivotal role in immune regulation and inflammatory modulation. Here, we report a potent and specific NLRP3 inhibitor Z48 obtained though docking-based virtual screening and structure-activity relationship studies with an IC50 of 0.26 μM in THP-1 cells and 0.21 μM in mouse bone marrow-derived macrophages. Mechanistic studies indicated that Z48 could bind directly to the NLRP3 protein (KD = 1.05 μM), effectively blocking the assembly and activation of the NLRP3 inflammasome, consequently manifesting anti-inflammatory properties. Crucially, with acceptable mouse pharmacokinetic profiles, Z48 demonstrated notable therapeutic efficacy in a mouse model of DSS-induced ulcerative colitis, while displaying no significant therapeutic impact on NLRP3KO mice. In conclusion, this study provided a promising NLRP3 inflammasome inhibitor with novel molecular scaffold, poised for further development as a therapeutic candidate in the treatment of inflammatory bowel disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy & Minhang Hospitol, Fudan University, Shanghai 201301, China.
- Department of Biopharmaceuticals, School of Pharmacy, Fudan University, Shanghai 201301, China.
- Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai 201301, China.
- Key Laboratory for Advanced Materials and Feringa Nobel Prize Scientist Joint Research Center, Institute of Fine Chemicals, School of Chemistry and Molecular Engineering, Frontiers Science Center for Materiobiology and…
ORCID-Profile: Chunchang Zhao, Xianfeng Gu
Förderung
- National Natural Science Foundation of China
- Institute of Fudan University-Quzhou
Zitieren
APA
Zhang, Z., Wu, H., Yin, K., Zheng, X., Cao, Z., Guo, W., Zhao, C., & Gu, X. (2024). Design, Synthesis, and Bioevaluation of Novel NLRP3 Inhibitor with IBD Immunotherapy from the Virtual Screen. Journal of Medicinal Chemistry, 67(18), 16612-16634. https://doi.org/10.1021/acs.jmedchem.4c01445
Vancouver
Zhang Z, Wu H, Yin K, Zheng X, Cao Z, Guo W, et al. Design, Synthesis, and Bioevaluation of Novel NLRP3 Inhibitor with IBD Immunotherapy from the Virtual Screen. Journal of Medicinal Chemistry. 2024;67(18):16612-16634. doi:10.1021/acs.jmedchem.4c01445
BibTeX
@article{Zhang2024,
author = {Zhang, Ziwen and Wu, Hongyu and Yin, Kai and Zheng, Xinru and Cao, Zhonglian and Guo, Wei and Zhao, Chunchang and Gu, Xianfeng},
title = {Design, Synthesis, and Bioevaluation of Novel NLRP3 Inhibitor with IBD Immunotherapy from the Virtual Screen},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {18},
pages = {16612--16634},
doi = {10.1021/acs.jmedchem.4c01445}
}
EUVIMED